.After a couple of years in biotech, Mike Quigley, Ph.D., is returning to the pharma crease, using up the top scientific research spot at Sanofi.Quigley will definitely begin Sept. 30 as the French Big Pharma’s primary medical officer as well as international head of investigation, Sanofi told Tough Biotech in an emailed statement.Quigley is replacing Frank Nestle, M.D., that left behind Sanofi this spring in the middle of an international overhaul of the provider’s R&D system. Nestle, that invested eight years along with the pharma, hopped over to Deerfield Control, where he presently acts as a companion on the therapies staff and also chief executive officer of the company’s therapeutic revelation and also growth functions.
Quigley will certainly participate in Sanofi coming from a San Francisco-based biotech that remains in stealth, depending on to his LinkedIn account. He’s currently listed as the company’s founder, president as well as CEO.Given that August 2021, Quigley has served as an endeavor companion at SV Health Investors, a medical care fund manager along with current assets in biotechs including BioAge, Cerevance, Dualitas Therapeutics as well as Nimbus Therapeutics, to name a few. Quigley formerly kept the leading area at Dualitas, a biotech that remains in secrecy, depending on to STAT.The prospective Sanofi forerunner also recently helmed Therini Bio, an immunotherapy biotech functioning to establish treatments for neurodegenerative illness steered by vascular problems.Prior to devoting the last couple of years in biotech, Quigley has an also longer record in Big Pharma, most just recently functioning as Gilead’s senior bad habit president of analysis the field of biology until the summer months of 2021.
Just before that, he appeared more than four years throughout several leadership roles at Bristol Myers Squibb as well as served as a medical supervisor at Johnson & Johnson’s Janssen upper arm before that.Sanofi pointed out Quigley’s mission in his brand new role would be actually to “optimize our possibility of effectiveness through optimal partnerships throughout our organization and past, carrying best-in-class technology and also cultivating as well as sourcing brand-new industry-leading skill along with a commitment to variety,” depending on to an inner memorandum acquired by STAT.